Global X Management Company’s Avadel Pharmaceuticals AVDL Stock Holding History

Global X Management Company’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,858	Closed	-$23K	–	901
2015 Q4	$23K	Buy	1,858 +85	+5%	+$1.32K	﹤0.01%	475
2015 Q3	$29K	Sell	1,773 -720	-29%	-$15.9K	﹤0.01%	431
2015 Q2	$53K	Sell	2,493 -2,028	-45%	-$36.4K	﹤0.01%	406
2015 Q1	$81K	Buy	4,521 +2,963	+190%	+$46.4K	﹤0.01%	323
2014 Q4	$27K	Buy	1,558 +54	+4%	+$771	﹤0.01%	409
2014 Q3	$22K	Sell	1,504 -530	-26%	-$7.62K	﹤0.01%	420
2014 Q2	$31K	Buy	+2,034	New	+$24.5K	﹤0.01%	387

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Global X Management Company's AVDL Position: Q1 2016 in Review

Global X Management Company sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 1,858 shares — an estimated $23K sold.

Global X Management Company first reported a position in AVDL in Q2 2014 and held it in 7 quarters. The position peaked at $81K in Q1 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

Global X Management Company reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Global X Management Company sold 1,858 Avadel Pharmaceuticals shares in Q1 2016, an estimated $23K.
Global X Management Company first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 7 quarters.
Global X Management Company's Avadel Pharmaceuticals position peaked at $81K in Q1 2015.
81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Global X Management Company's 13F filing for Q1 2016, filed 6 May 2016.